Psychedelic Bulletin #102 – Our Analysis of MindMed’s LSD for Anxiety Results; Mail-Order Ketamine May Come Under Scrutiny; Our Notes from PSYCH Symposium Post published:May 16, 2022 Post category:Psychedelic Bulletin
Psychedelic Research Bulletin: April 2022 Post published:May 12, 2022 Post category:Psychedelics Research Review
Psychedelic Bulletin #101 – Psychedelic R&D in the UK; COMPASS Study Points to Psilocybin for Anorexia Post published:May 6, 2022 Post category:Psychedelic Bulletin
Psychedelic Bulletin: Psychedelics X Big Pharma; $23m Round for At-Home Ketamine Therapy; Psychedelics Research Review Post published:April 25, 2022 Post category:Psychedelic Bulletin
Psychedelic Research Bulletin: March 2022 Post published:April 24, 2022 Post category:Psychedelics Research Review
MYND Life Sciences Announces $3.5 Million Share Offering Post published:April 21, 2022 Post category:Press Release
Cybin Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder Post published:April 21, 2022 Post category:Press Release
COMPASS Pathways partners with One Mind to fund Rising Star Awards for the next generation of mental health researchers Post published:April 20, 2022 Post category:Press Release
Mindset Pharma Strengthens IP Portfolio with Another New Provisional Patent Application Covering its Next-Generation DMT and 5-MeO-DMT Drug Candidate Compounds Post published:April 19, 2022 Post category:Press Release